Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4647-4651

  Massaad Massade, Liliane ^a,b   Ribrag, Vincent ^a   Marie, Jean Pierre ^c   Faussat, Anne Marie ^c   Bayle, Chantal ^a   Dreyfus, François ^d   Gouyette, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c HÔTEL DIEU   (France)

^d ICGM: INSERM U 363 ^*  (France)

Author keywords

Acute myelogenous leukemia; Glutathione system; Multidrug resistance phenotype; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SPECTROPHOTOMETRY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LEUKEMIA, MYELOCYTIC, ACUTE; LOMUSTINE; MONOCYTES; P-GLYCOPROTEIN; PHENOTYPE; RECURRENCE; REMISSION INDUCTION;

EID: 0031427216     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Stone RM, Mayer RJ: Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol/Oncol Clin North Am 7: 47-64, 1993.
2. Whittaker JA: Acute myeloblastic leukemia. In: Whittaker JA, Ed. Leukaemia. Oxford: Blackwell, 1992.
3. Jones L, Newland AC: The management of relapsed and refractory acute myeloid leukemia in adults. Leukemia and lymphoma 4: 93-98, 1991.
4. Davis CL, Rohatiner AZS, Lim J, et al: The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol 83: 404-411, 1993.
5. Grever MR: Treatment of patients with acute nonlymphocytic leukemia not in remission. Semin Oncol 14: 416-424, 1987.
6. Marie JP: P-Glycoprotein in adult hematologic malignancies. Hematol/Oncol Clin North Am 9: 239-249, 1995.
7. Davies SM, Robson CN, Davies SL, et al: Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263: 17724-17729, 1988.
8. Webb CD, Latham MD, Lock Rb, et al: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543-6549, 1991.
9. Deffie AM, Batra JK, Goldenberg GJ: Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
10. Kaufmann SH, Karp JE, Jones RJ, et al: Topoisomerase II levels and drug sensitivity in adult myelogenous leukemia. Blood 83: 517-530, 1994.
11. McKenna SL, Whittaker JA, Padua RA, et al: Topoisomerase II expression in normal hematopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance ? Leukemia 7: 1199-1203, 1993.
12. Potmesil M, Hsiang YH, Liu LF, et al: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543, 1988.
13. Habig WH, Pabst MJ, Jakoby WB: Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139, 1974.
14. Jacoby WB, and Habig WH: Glutathione -S-transferases. In : W.B. Jackoby (ed.), enzymatic basis of detoxication, Vol. II, pp. 63-94. New York: Academic Press, 1980.
15. Mannervik B: The isoenzymes of glutathione-S-transferase. Adv Enzymol 57: 357-417, 1985.
16. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320, 1994.
17. Kremers P, Beaune PH, Cresteil T, et al: Cytochrome P-450 monooxygenase activity in human and rat liver microsomes. Eur J Biochem 118: 599-606, 1981
18. Drake FH, Zimmerman JP, McCabe FL, et al: Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J Biol Chem 262: 16739-16747, 1987.
19. Laemmli UK: Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature (Lond.) 227: 680-685, 1970.
20. Massaad L, de Waziers I, Ribrag V, et al: Comparison of mouse and human tumors with regard to phase I and phase II drug-metabolizing enzymes systems. Cancer Res 52: 6567-6575, 1992.
21. Kaufmann SH, McLaughlin SJ, Kastan MB, et al: Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51: 3534-3543, 1991.
22. Akerboom TP, Sies H: Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 77: 373-384, 1981.
23. Smith PK, Krohn RI, Hermanson GT, et al: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
24. Schwartz D: Méthodes statistiques à l'usage des médecins et des biologistes. Flammarion Médecine-Sciences, Troisième édition, 1975.
25. Alton PA, Harris AL: The role of DNA topoisomerase II in drug resistance. Br J Haematol 85: 241-245, 1993.
26. Beck WT, Grogan TM, Willman CL, et al: Methods to detect P-glycoprotein-associated multidrug resistance in patients£ tumors: Cnsensus recommendations. Cancer Res 56: 3010-3020, 1996.
27. Marie J-P, Huet S, Faussat A-M, et al: Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 11: 1086-1094, 1997.
28. Xu D, Knaust E, Pisa P, et al: Levels of mdr1 and mrp mRNA in leukemic cell populations from patients with acute myelocytic leukemia are heterogenous and inversly correlated to cellular daunorubicin accumulation. Br J Haematol 92: 847-854, 1996.
29. Tidefelt U, Elmohorn-Rosenborg A, Paul C, et al: Expression of glutathione transferase p as a predictor for treatment results at different stages of acute nonlymphocytic leukemia. Cancer Res 52: 3281-3285, 1992.